Pines Wealth Management LLC Takes $276,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Pines Wealth Management LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,179 shares of the medical instruments supplier's stock, valued at approximately $276,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Sound Income Strategies LLC boosted its position in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier's stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Central Pacific Bank Trust Division raised its stake in shares of Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier's stock worth $59,000 after purchasing an additional 45 shares in the last quarter. Tompkins Financial Corp lifted its holdings in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 46 shares during the last quarter. Birch Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 0.4% in the 3rd quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier's stock valued at $2,838,000 after buying an additional 48 shares in the last quarter. Finally, Radnor Capital Management LLC increased its holdings in Becton, Dickinson and Company by 1.7% in the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier's stock worth $708,000 after buying an additional 48 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

BDX stock traded up $3.64 during mid-day trading on Thursday, reaching $236.23. 1,515,779 shares of the stock traded hands, compared to its average volume of 2,075,454. The firm has a market capitalization of $68.51 billion, a PE ratio of 39.77, a P/E/G ratio of 1.69 and a beta of 0.39. The business has a 50-day moving average of $226.92 and a two-hundred day moving average of $232.50. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $248.42. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm's revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.42 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 9th were paid a dividend of $1.04 per share. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.76%. The ex-dividend date was Monday, December 9th. Becton, Dickinson and Company's dividend payout ratio is presently 70.03%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 2,838 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the sale, the executive vice president now owns 6,141 shares of the company's stock, valued at approximately $1,371,469.53. This trade represents a 31.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roland Goette sold 638 shares of the company's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares of the company's stock, valued at $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,747 shares of company stock valued at $1,949,520 in the last ninety days. Company insiders own 0.36% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on BDX shares. StockNews.com downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Evercore ISI increased their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Finally, Citigroup raised Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $283.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.